Clinically relevant drug–drug interactions between antiretrovirals and antifungals
Year: 2014
Type: review
Abstract: INTRODUCTION: Complete delineation of the HIV-1 life cycle has resulted in the development of several antiretroviral drugs. Twenty-five therapeutic agents belonging to five different classes are currently available for the treatment of HIV-1 infections. Advent of triple combination antiretroviral therapy has significantly lowered the mortality rate in HIV patients. However, fungal infections still represent major opportunistic diseases in immunocompromised patients worldwide. AREAS COVERED: Antiretroviral drugs that target enzymes and/or proteins indispensable for viral replication are discussed in this article. Fungal infections, causative organisms, epidemiology and preferred treatment modalities are also outlined. Finally, observed/predicted drug-drug interactions between antiretrovirals and antifungals are summarized along with clinical recommendations. EXPERT OPINION: Concomitant use of amphotericin B and tenofovir must be closely monitored for renal functioning. Due to relatively weak interactive potential with the CYP450 system, fluconazole is the preferred antifungal drug. High itraconazole doses (> 200 mg/day) are not advised in patients receiving booster protease inhibitor (PI) regimen. Posaconazole is contraindicated in combination with either efavirenz or fosamprenavir. Moreover, voriconazole is contraindicated with high-dose ritonavir-boosted PI. Echinocandins may aid in overcoming the limitations of existing antifungal therapy. An increasing number of documented or predicted drug-drug interactions and therapeutic drug monitoring may aid in the management of HIV-associated opportunistic fungal infections.
Institution: University of Missouri–Kansas City
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: drug-drug interactions, antiretroviral drugs, antifungal agents, HIV-associated fungal infection, opportunistic fungal infection, HIV-1, amphotericin B, tenofovir, fluconazole, itraconazole, posaconazole, voriconazole, ritonavir-boosted protease inhibitors, efavirenz, fosamprenavir, echinocandins, renal function monitoring, therapeutic drug monitoring, cytochrome P450
Open Access status: green
OpenAlex ID: W2096734724
